As apparent from the parallel development of drugs combining GLP1R agonism with either GIPR agonists or antagonists for the treatment of obesity, GIP appears to have several, sometimes opposing, actions on the brain. Here, GLP1R is linked to obesity due to melanocortin 4 receptor deficiency.